20 articles
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
A large VA study finds SGLT2 inhibitors cut dementia risk by nearly 40% in older adults with depression, bipolar disorder, or schizophrenia.
New data from ASCO shows GLP-1 drugs like semaglutide may dramatically slow cancer progression in colorectal, liver, breast, and lung cancer patients.
A large cohort study finds GLP-1 receptor agonists slash obesity-linked cancer risk by 41%, with tirzepatide outperforming semaglutide dramatically.
Phase III trials show once-weekly CagriSema outperforms placebo on HbA1c and body weight in multiple type 2 diabetes populations.
Two adolescents with T1D and obesity saw major metabolic gains from low-dose semaglutide, cutting insulin needs and improving blood sugar control.
A large EHR analysis finds GLP-1 users face a 48% higher relative risk of sensory disturbances — though absolute increases remain tiny.
New data from 111,000+ women shows GLP-1 agonists cut breast cancer rates by 30%, spurring a major prevention trial.
A roundup of endocrinology breakthroughs: GLP-1s post-surgery, vitamin D cutting diabetes risk, and resistance training protecting 140,000 professionals.
Tirzepatide outperforms semaglutide on weight loss but may strip more muscle. Plus: fructose, keto diets, and cardiac benefits of oral GLP-1s.
From new GLP-1 weight loss data to Omnipod recalls and semaglutide for nicotine addiction, here's what's moving in endocrinology.
AstraZeneca's oral GLP-1 drug elecoglipron showed meaningful weight loss and blood sugar reduction in two mid-stage trials published in the Lancet.
A large records review finds semaglutide users had significantly fewer bone fractures than those on other diabetes or weight-loss drugs.
The ACHIEVE-5 trial shows orforglipron added to basal insulin significantly lowered HbA1c and reduced body weight without raising hypoglycemia risk.
Two patients developed rare choroidal eye disease on dulaglutide; vision fully recovered after stopping the GLP-1 drug.
New research shows diabetes and weight-loss medications slow alcohol absorption, making people feel less intoxicated and potentially reducing drinking.
The FDA proposes removing semaglutide, tirzepatide, and liraglutide from compounding lists, tightening access to cheaper GLP-1 alternatives.
A large 10-year study finds GLP-1 users develop cognitive impairment more often — but mainly because they live longer to face it.
New research finds GLP-1 receptor agonists may dramatically cut age-related macular degeneration risk compared to other medications.
The FDA proposes removing semaglutide, tirzepatide, and liraglutide from the compounding bulks list, restricting cheaper alternatives.
